serine palmitoyltransferase long chain base subunit 1 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored SPTLC1P3 profile across patient tissues and cancer cell-line models. SPTLC1P3 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SPTLC1P3 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, SPTLC1P3 RNA expression shows 4,552 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, HNSC, and STAD as cancer lineages where SPTLC1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTLC1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTLC1P3 survival associations across molecular data types. SPTLC1P3 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTLC1P3 RNA expression–survival associations across cancer types. High SPTLC1P3 expression shows unfavorable associations in BLCA, LUAD, COAD, PCPG and GBM, but favorable associations in LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SPTLC1P3 RNA expression.
This table summarizes SPTLC1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPTLC1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTLC1P3 shows higher tumor expression in HNSC. The HNSC box plot shows higher SPTLC1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.254, t-test p = .013).
This table shows molecular features associated with SPTLC1P3 in patient tissues and cancer cell lines. In patient samples, SPTLC1P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
